GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyra Therapeutics Inc (NAS:LYRA) » Definitions » Selling, General, & Admin. Expense

Lyra Therapeutics (Lyra Therapeutics) Selling, General, & Admin. Expense : $19.75 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lyra Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Lyra Therapeutics's selling, general, & admin. expense for the three months ended in Mar. 2024 was $5.82 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $19.75 Mil.


Lyra Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Lyra Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyra Therapeutics Selling, General, & Admin. Expense Chart

Lyra Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 4.49 9.69 14.21 17.56 19.06

Lyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.13 4.57 5.00 4.36 5.82

Competitive Comparison of Lyra Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Lyra Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyra Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Lyra Therapeutics's Selling, General, & Admin. Expense falls into.



Lyra Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyra Therapeutics  (NAS:LYRA) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Lyra Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Lyra Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyra Therapeutics (Lyra Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Executives
Harlan Waksal director, officer: Executive Chair WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nbvm Gp, Llc 10 percent owner 950 WINTER STREET, SUITE 4600, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Edward T Anderson director, 10 percent owner 950 WINTER ST SUITE 4600, WATHAM MA 02451
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Richard Nieman officer: Chief Medical Officer C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
C Ann Merrifield director
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jason Cavalier officer: Chief Financial Officer C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Pamela E. Nelson officer: Senior VP, Regulatory Affairs C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Robert E. Richard officer: SVP of R&D C10 LYRA THERAPEUTICS, INC., 1480 ALSENAL WAY, WATERTOWN MA 02472
Soleus Private Equity Fund I, L.p. 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Soleus Capital, Llc 10 percent owner 104 FIELD POINT ROAD, FLOOR 2, GREENWICH CT 06830
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210